How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator.
Giorgio GandagliaRoderick C N van den BerghDerya TilkiNicola FossatiPiet OstChristian I SurcelPrasanna SooriakumaranIgor TsaurMassimo ValerioAlexander KretschmerEmanuele ZaffutoLaurent SalomonFrancesco MontorsiMarkus GraefenHendrik van der PoelAlexandre de la TailleAlberto BrigantiGuillaume Ploussardnull nullPublished in: BJU international (2018)
The use of a novel risk score for AS selection would result in an absolute increase of 10% in the number of patients eligible for this approach without increasing the risk of misclassification.